No­var­tis' PI3K drug, al­ready ap­proved in breast can­cer, nabs a speedy OK to treat ul­tra-rare con­di­tion

Half a year af­ter No­var­tis show­cased the po­ten­tial of its PI3K in­hibitor alpelis­ib among a group of young pa­tients with an ul­tra-rare con­di­tion, the FDA has green­light­ed the drug’s use based sole­ly on re­al-world ev­i­dence.

Brand­ed Vi­joice, it is the first and on­ly treat­ment aimed at the root cause of PIK3CA-re­lat­ed over­growth spec­trum (PROS), ac­cord­ing to No­var­tis, a dis­ease es­ti­mat­ed to af­flict 14 peo­ple per mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.